Understanding how lung cancer adapts to new therapies
Official title: Mechanisms of adaptation and resistance to emerging therapies for lung cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11065478 · Data updated 2026-11-12
This study is looking at how lung cancer cells change and become resistant to new treatments, especially for those with a specific KRAS mutation, to help find better ways to treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $514,185 |
| NIH project number | 5R01CA279264-03 |
| Project ID | NIH-11065478 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung cancer who have KRAS G12C mutations.
✕Less likely to help
Patients with lung cancer who do not have KRAS mutations may not benefit from this research.
What this research studies
This research investigates the mechanisms by which lung cancer cells adapt and develop resistance to emerging therapies, particularly those targeting the KRAS G12C mutation. By studying the biological processes involved, the research aims to identify factors that influence treatment effectiveness and resistance. Patients with lung cancer, especially those with KRAS mutations, may benefit from insights gained through this research, which could lead to improved therapeutic strategies. The approach includes analyzing cancer cell behavior and responses to specific inhibitors that have shown promise in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients with KRAS mutations, potentially improving survival rates.
How similar studies have gone: Other research has shown success in targeting KRAS mutations, particularly with the development of specific inhibitors like sotorasib, indicating a promising avenue for further exploration.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lito, Piro — Sloan-Kettering Inst Can Research
- Study coordinator: Lito, Piro
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.